All patients with AML and FLT3/ITD should be transplanted in first remission. Also in the era of tyrosine kinase inhibitors? – the PRO

All patients with AML and FLT3-ITD should be transplanted in first remission.Also in the era of tyrosine kinase inhibitors? -

Authors

Institutions

Publication Details

Journal
Haematologica
Published
2026-01-15
DOI
https://doi.org/10.3324/haematol.2025.288785
Primary Topic
Acute Myeloid Leukemia Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

All patients with AML and FLT3/ITD should be transplanted in first remission. Also in the era of tyrosine kinase inhibitors? – the PRO

Sabine Käyser, Richard F. Schlenk
Haematologica
Acute Myeloid Leukemia Research
article

All patients with AML and FLT3/ITD should be transplanted in first remission. Also in the era of tyrosine kinase inhibitors? – the PRO

Sabine Käyser, Richard F. Schlenk
article en

Abstract

All patients with AML and FLT3-ITD should be transplanted in first remission.Also in the era of tyrosine kinase inhibitors? -

Haematologica
German Cancer Research Center (DE), Heidelberg University (DE), German Red Cross (DE), University Hospital Heidelberg (DE), National Center for Tumor Diseases (DE)
Pfizer, AstraZeneca, Jazz Pharmaceuticals, PharmaMar, Daiichi Sankyo Europe
Openalex Percentile: Top 88%
Acute Myeloid Leukemia Research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.